CRBU Q3 2023 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CRBUCaribou Biosciences, Inc.

$186M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$24M+616.4% YoY

Gross Profit

-$5M-20.8% margin

Operating Income

-$15M-61.8% margin

Net Income

-$10M-42.3% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+530.1%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$34M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$458M

Total Liabilities

$59M

Stockholders' Equity

$398M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24M	$3M	+616.4%
Gross Profit	-$5M	$3M	-249.0%
Operating Income	-$15M	-$27M	+44.9%
Net Income	-$10M	-$27M	+62.5%

Geographic Segments

UNITED STATES

$23M98%

Non-US

$377,0002%